It is well established that the growth of antimicrobial resistance is a major challenge to future human health. At the same time fewer new compounds are being developed with most compounds failing between ‘hit to lead’ and the end of pre-clinical development. 
Created in 2012, BIOASTER is a French not-for-profit technology research institute dedicated to microbiology and infectious diseases with the mission to lead collaborative projects with public and private partners for the benefit of patients. We are not a pharma company, so we don’t develop drugs and hence we will not dilute your IP. We develop technologies to help our partners discover better drugs faster. We can add value to our partners’ projects at every stage from target identification through in-vivo proof of concept in small rodents. Our technology units cover all the drug discovery activities (except synthesis and toxicology) including but not limited to: microbiology, bacterial genomics and transcriptomics, screening and profiling, bespoke murine models of infection, PK/PD studies, biofilms inhibition, resistance prediction, MoA novelty assessment, combination therapies, alternative approaches to antibiotics. We have also worked with our partners on the major pathogens (ESKAPE, E. coli, C. difficile, Streptococci, M. tuberculosis etc...)

We would be delighted to talking to you about our experience on the following topics that could be interesting to you:
For bacteriocin and ectolysin
•	Specificity: We can test your compounds on very diverse collection of bacteria including commensal anaerobic ones
•	Synergy with antibiotic standards of care: We can assess synergism (or additivity or antagonism) in vitro and quantify the best concentration ratio
•	PK we can perform multicomponent PK in order to optimize a combination therapeutic regimen
•	Efficacy: Bespoke longitudinal study through in vivo imaging (bioluminescent bacterial pathogens)
•	PK/PD 
•	In vivo effect of compounds on a controlled commensal flora in a gnotobiotic murine model
For phages
•	Variable route of administration
•	Biodistribution in different organs
•	Efficacy: Bespoke longitudinal study through in vivo imaging (bioluminescent bacterial pathogens)
•	Monitoring of immune response during treatment
•	Evaluation of multiple treatments on efficacy